| Edition |
First edition. |
| Description |
1 online resource : color illustrations |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
Micro & nano technologies series |
|
Micro & nano technologies.
|
| Note |
Print version record. |
| Bibliography |
Includes bibliographical references and index. |
| Contents |
Front Cover; Nucleic Acid Nanotheranostics: Biomedical Applications; Copyright; Dedication; Contents; Contributors; Preface; Acknowledgments; Chapter 1: Therapeutic Oligonucleotides Against Cancer: Recent Approaches and New Perspectives; 1. Introduction; 2. Mechanisms of Action; 2.1. Antisense Oligodeoxynucleotides (AS-ODNs); 2.2. Small Inhibitory RNAs (siRNAs) and microRNAs (miRNAs); 2.3. Immunostimulatory ODNs (IMOs); 2.4. Catalytic Oligonucleotides (DNAzymes and Ribozymes); 2.5. Aptamers; 3. Delivery; 3.1. Physiological Barriers for TONs Activity; 3.2. Delivery of Naked TONs |
|
3.3. Conjugated TONs3.4. Delivery of Encapsulated TONs; 3.4.1. Lipidic Carriers; 3.4.2. Nonlipidic Bionanoparticles; 3.4.3. Polymeric Carriers; 4. Therapeutic Antisense Oligodeoxynucleotides (AS-ODNs) in Cancer; 5. Small Interfering RNA (siRNA); 6. MicroRNA (miRNA); 7. Catalytic Oligonucleotides (DNAzymes and Ribozymes); 8. Aptamers; 9. Conclusions; References; Chapter 2: Small Interfering RNA-Mediated Silencing of the Ribophorin II Gene: Advances in the Treatment of Malignant Bre ... ; 1. Introduction; 2. Biology of RPN2; 2.1. Regulation of Chemoresistance; 2.1.1. Breast Cancer |
|
3.2. Toxicity test for RPN2-siRNA4. Conclusion; Acknowledgments; References; Chapter 3: Noncoding RNAs in Cardiovascular Disease; 1. Introduction; 2. Micro-RNAs; 2.1. Biogenesis; 2.2. Mechanism of Action; 3. Long Noncoding RNAs; 3.1. Biogenesis; 3.2. Mechanisms of Action; 3.3. Nuclear lncRNA; 3.3.1. Lnc-RNA-Mediated Methylation; 3.3.2. Direct Heterochromatin Formation; 3.3.3. Transcriptional Interference; 3.3.4. Decoy; 3.3.5. Polymerase II Inhibitors; 3.3.6. Transcriptional Coregulators; 3.3.7. Paraspeckles; 3.3.8. Splicing Modulation; 3.4. Cytoplasmic lncRNAs |
|
3.4.1. mRNA Stability Modulation3.4.2. Translational Regulation; 3.4.3. miRNA-lncRNA Interaction; 4. Role of miRNA and lncRNA in Cardiovascular Development and Disease; 4.1. miRNA in Cardiovascular Development; 4.2. miRNA in Cardiovascular Disease; 4.2.1. Fibrosis; 4.2.2. Cardiomyocyte Hypertrophy; 4.2.3. Myocardial Infarction; 4.2.4. Myosin Switching; 4.3. lncRNA in Cardiovascular Development; 4.4. lncRNA in Cardiovascular Disease; 5. ncRNA Therapeutics; 5.1. siRNA and miRNA Therapeutics; 5.1.1. Chemical Modifications to Increase Stability; 5.1.1.1. Backbone Modifications |
| Subject |
Nucleic acids.
|
|
Nanomedicine.
|
|
Biomedical materials.
|
|
Nucleic Acids -- therapeutic use |
|
Drug Carriers -- therapeutic use |
|
Theranostic Nanomedicine -- methods |
|
Nanomedicine |
|
MEDICAL -- Anatomy.
|
|
SCIENCE -- Life Sciences -- Human Anatomy & Physiology.
|
|
Biomatériaux.
|
|
Nanomédecine.
|
|
MEDICAL -- Anatomy.
|
|
SCIENCE -- Life Sciences -- Human Anatomy & Physiology.
|
|
Biomedical materials
|
|
Nanomedicine
|
|
Nucleic acids
|
| Genre/Form |
Electronic books.
|
| Added Author |
Filice, Marco, editor.
|
|
Ruiz-Cabello, Jesús, editor.
|
| Other Form: |
Print version: NUCLEIC ACID NANOTHERANOSTICS. [Place of publication not identified], ELSEVIER, 2019 012814470X (OCoLC)1040623005 |
| ISBN |
9780128144718 (electronic bk.) |
|
0128144718 (electronic bk.) |
|
012814470X |
|
9780128144701 |
| Standard No. |
AU@ 000065087017 |
|
UKMGB 019252564 |
|
AU@ 000065196525 |
|
AU@ 000066135820 |
|
